SynthesisJournal of human hypertension2026
Efficacy of pharmacological agents for management of post-partum hypertension: A systematic review and network meta-analysis.
Synthesis in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postpartum hypertension is a frequent cause of maternal morbidity and mortality. The objective of this study was to compare the effectiveness and safety of pharmacological agents for management of postpartum hypertension. We searched the MEDLINE and Embase through July 2025. The studies which were randomized controlled trials enrolling women with postpartum hypertension. Eligible trials compared active agents or placebo/usual care and reported blood pressure outcomes. Primary outcomes were time to achieve blood pressure control (hours) and proportion of women achieving blood pressure control within seven days postpartum. Bayesian random-effects network meta-analysis was performed with Metainsight. Thirteen randomized controlled trials were identified. For time to blood pressure control, amlodipine and nifedipine ranked highest. Compared with labetalol, amlodipine reduced time to control blood pressure by 5.85 h and nifedipine by 5.11 h. Rankings indicated Calcium Channel Blockers were most effective for rapid control, followed by labetalol. For the proportion achieving control within seven days, labetalol ranked highest, with a probability near 100%. Compared with labetalol, risk ratios for blood pressure control were 1.01 for nifedipine, 1.03 for hydralazine, and 1.31 for hydrochlorothiazide-lisinopril. SUCRA values ranked labetalol highest, followed by nifedipine, hydralazine, and hydrochlorothiazide-lisinopril. Calcium channel blockers appear most effective for rapid reduction of blood pressure after childbirth, while labetalol is most reliable for sustained control within the first postpartum week. These findings provide a comparative framework for treatment selection and emphasize the need for larger, rigorously designed postpartum hypertension trials.PROSPERO Registration Number: CRD420251104693.
Indexed as
Identifiers
41663753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.